Studies suggest that staurosporine and venetoclax, which activate caspase-dependent proteolysis of MEF2D fusion proteins and apoptosis in MEF2D fusion+ ALL cells, may be effective in the treatment of ALL with MEF2D rearrangements [255]. This evidence concerns the gene MEF2D and acute lymphoblastic leukemia.